This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Bank ETFs to Consider on a Steepening Yield Curve
by Sweta Killa
Investors seeking to take advantage of the steep yield curve should bet on bank ETFs.
4 Reasons for Bank ETFs to Win in 2021
by Sanghamitra Saha
Bank ETFs should stay strong in the coming days on the back of cheaper valuation, Fed's signal for buybacks, Democrat's control over Senate and spike in bond yields.
6 Predictions for the ETF World in 2021
by Sanghamitra Saha
These ETF trends may rule the market in 2021
Top ETF Stories of Fourth-Quarter 2020
by Sanghamitra Saha
The year 2020 as a whole could easily be attributed to the COVID-19 outbreak.
5 Reasons to Pick JPMorgan (JPM) Over Bank of America (BAC)
by Zacks Equity Research
Given the solid revenue and earnings prospects, and efforts to further diversify businesses via strategic buyouts, JPMorgan (JPM) seems to be a better stock to bet on now compared with Bank of America.
5 ETFs to Buy as Fed Maintains Bond Buying
by Sanghamitra Saha
As widely expected, the Fed held interest rates steady at near-zero level in its latest meeting and maintained bond buying. However, the Fed beefed up growth projections for the U.S. economy.
Sector ETFs to Win & Lose on Oil Price Rebound
by Sanghamitra Saha
This has been a tough year for the oil sector with prices tumbling in the first half of the year and gaining in the latter half of the year.
ETFs to Play as Vaccine News Looks to Outdo Virus Fear
by Sanghamitra Saha
After almost a year-long wait, the month of November started delivering sweet surprises to investors in the form of back-to-back vaccine news.
Value or Growth: Which ETFs to Play Ahead?
by Sanghamitra Saha
If things turn right on the vaccine front in the coming days, one can surely expect a rise in economic activity and bond yields, and a rally in value stocks.
Time to Rotate to Cyclical Sector ETFs?
by Sanghamitra Saha
U.S. stocks have been super steady this week on Pfizer's upbeat vaccine data and chances of a divided Congress in the United States.